Jennifer E. Murphy

Dr. Jennifer E. Murphy


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SASarina Ailawadi
Sarina Ailawadi
JMJennifer E. Murphy
Jennifer E. Murphy
MSMichael H. Storandt
Michael H. Storandt
AMAmit Mahipal
Amit Mahipal
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk factor for pancreatic cancer, yet the impact of GLP-1 RA therapy in this high-risk population is unknown. In this study, we aimed to evaluate the association between GLP-1 RA use and pancreatic cancer incidence among patients with CP, and among those with CP and T2DM. Methods: We performed a retrospective cohort study using data from TriNetX, a healthcare database of over 150 million patients in the United States. In the first analysis, adult patients with pre-existing CP were identified and stratified by use of a GLP-1 RA (semaglutide, dulaglutide, tirzepatide, exenatide, liraglutide, lixisenatide, and albiglutide). Propensity score matching (PSM) was conducted between GLP1-RA users and non-users, matching for age, sex, race, tobacco use, alcohol use, hypertension, hyperlipidemia, obesity, and pancreatic cysts. Five-year incidence of pancreatic cancer was compared between GLP-1 RA users and non-users in the matched cohort between 2015 and 2025. We then restricted the cohort to patients with CP and T2DM and repeated this analysis. Results: We identified 89,596 patients with CP, including 3183 GLP-1 RA users and 86,413 non-users. After PSM, GLP-1 RA use was associated with a lower 5-year incidence of pancreatic cancer (hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.30–0.80, p < 0.005). Similarly, amongst patients with CP and T2DM, GLP-1 RA use was associated with a lower 5-year incidence of pancreatic cancer (HR 0.53, 95% CI 0.31–0.91, p < 0.05). Conclusions: GLP-1 RA use was associated with a significantly reduced incidence of pancreatic cancer in all patients with CP, as well as the subpopulation with both CP and T2DM. Given the elevated cancer risk in CP, these findings suggest a potential beneficial effect of GLP-1RA use in this high-risk population. Prospective studies will be important to further analyze and confirm this potential benefit.

6 June 2025 in Neurosurgery
Verified
Journal Article
Open access
JBJordan Black
Jordan Black
ISIshan Singhal
Ishan Singhal
JMJennifer E. Murphy
Jennifer E. Murphy
MSMichael D. D Staudt
Michael D. D Staudt
BACKGROUND AND OBJECTIVES: The placement of spinal cord stimulators (SCSs) relies on midline placement to provide bilateral coverage. Implantation under general anesthesia using intraoperative neuromonitoring (IOM) has been shown to be a valid alternative to awake placement to confirm positioning. It has been suggested that placement should be confirmed with awake testing or IOM for reasons of efficacy and safety. No study has compared operative outcomes in percutaneous SCS surgery with our without the use of IOM. METHODS: A single-center retrospective chart review was performed, identifying 228 patients who underwent percutaneous SCS implantation between 2021 and 2023 by a single surgeon. Surgery was performed with IOM (n = 55) or without IOM (n = 173). The primary outcome measures were laterality of coverage, revision and explant rates, and incidence of intraoperative complications. Secondary outcomes included pain severity scores (Numerical Rating Scale) and operative duration. RESULTS: All patients had bilateral stimulation coverage regardless of IOM, and no revisions for laterality occurred. Revision rates for fracture of migration did not significantly vary between cohorts (IOM 3.6%, non-IOM 4.0%; P > .999). Explantation rates were also not significantly different (IOM 9.1%, non-IOM 5.2%; P = .334). Patients in both cohorts demonstrated a lower Numerical Rating Scale at last follow-up compared with baseline; however, this change did not significantly vary between cohorts (IOM 4.7 vs non-IOM 4.4; mean difference: 0.26; P = .713) nor did the proportion of responders (IOM 52.6% vs non-IOM 48.9%; P = .684). Operative duration was significantly longer in the IOM cohort (65.3 vs 48.6 minutes; mean difference: 16.5 minutes; P < .001), as was “room-to-incision” time (41.0 vs 33.3 minutes; mean difference 7.66 minutes; P < .001). No intraoperative complications were encountered in either cohort, including no nerve irritation or neurological injury. CONCLUSION: Percutaneous SCS placement can safely and accurately be performed without the use of IOM. IOM does not improve placement accuracy or laterality of coverage, as long as leads are placed anatomically in the midline.

21 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SASarina Ailawadi
Sarina Ailawadi
SMSepideh Mehravar
Sepideh Mehravar
JMJennifer E. Murphy
Jennifer E. Murphy
MSMichael H. Storandt
Michael H. Storandt
AMAmit Mahipal
Amit Mahipal
Background: Atezolizumab plus bevacizumab (A + B) and durvalumab plus tremelimumab (D + T) are approved first-line systemic therapy options for advanced hepatocellular carcinoma (HCC), with no head-to-head comparison. In this propensity-matched analysis, we compared the survival of patients with advanced HCC who received either A + B or D + T therapy. Methods: Patients with advanced HCC who received A + B or D + T treatment in the first-line setting were identified using the TriNetX platform, a health research network that provides access to electronic health record data from 112 healthcare organizations. Propensity-score-matched (PSM) analysis was conducted, and the median overall survival (OS) was estimated using the Kaplan–Meier method. Results: We identified 2819 patients with HCC who were treated with A + B or D + T: 2031 patients received A + B and 788 received D + T. Compared to patients in the A + B cohort, those who received D + T were more likely to be older (median age: 68.4 vs. 66.9 years), have lower platelet counts (186.8 vs. 201.3), higher prevalence of hypoalbuminemia with levels < 2.7 g/dL (35.2% vs. 28.4%), higher prevalence of bilirubin levels between 2.0 and 2.9 mg/dL (28.8% vs. 23.8%), and decreased INR with levels between 0.0 and 1.6 (92.1% vs. 86.3%). After PSM, 1536 patients were included in the survival analyses, with all variables adequately matched. There was no significant difference in the median OS between those receiving A + B or D + T [16.3 vs. 22.5 months, hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.76–1.0]. Higher rates of immune-mediated colitis were noted in the D + T group. Conclusions: Similar survival rates were observed among patients with advanced HCC who received A + B and D + T in the first-line setting. Our study suggests that both A + B and D + T are valid treatment options, and that therapy can be tailored based on comorbidities, adverse effects, and patient preferences.

11 April 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
ZKZiad Koberssy
Ziad Koberssy
AFAaron Andrew Fletcher
Aaron Andrew Fletcher
JDJoviane Daher
Joviane Daher
JMJennifer E. Murphy
Jennifer E. Murphy
JBJhony Baissary
Jhony Baissary
GMGrace A McComsey
Grace A McComsey
Background/Objectives: People with HIV (PWH) remain at high risk for cardiovascular and metabolic complications despite effective antiretroviral therapy (ART). Diet quality is an important modifiable factor that may influence these complications. Diets high in ultra-processed foods (UPF) have been linked to adverse metabolic and inflammatory profiles in the general population, but their impact on PWH remains poorly understood. The NOVA 4 classification categorizes foods by degree of processing, from unprocessed/minimally processed (NOVA 1) to UPF (NOVA 4). Methods: We conducted a cross-sectional study of adults with virologically suppressed HIV on stable ART. Assessments included dietary intake consisting of 24 h recalls analyzed with Nutrition Data System for Research software (NDSR) and classified into NOVA categories by a registered dietitian and the following characteristics: body composition (total and regional fat by DEXA and CT scan abdomen), cardiometabolic variables (glucose, HbA1C, HOMA-IR, lipids, blood pressure), and biomarkers of inflammation, immune activation, and gut integrity quantified by ELISA. Patients were stratified into NOVA 4 groups based on the median and quartile proportions of total energy intake from NOVA 4 foods. Associations between dietary NOVA and outcomes were analyzed using generalized additive models (GAMs) adjusted for age, sex, race, and CD4 count. Results: Among 222 PWH (mean age 45.4 ± 14.2 years; 31% female; 66% non-white; BMI 30.61 ± 7.91 kg/m2), median NOVA 4 intake was 45.6% of total energy intake. Participants with higher vs. lower NOVA 4 intake showed differences in diet quality, but in GAMs, higher NOVA 4 intake was not associated with higher levels of inflammatory, cardiometabolic, gut integrity, and body composition variables. Conclusions: In PWH, UPF consumption was high but not associated with markers of cardiometabolic health, systemic inflammation, or gut integrity. This may reflect the multifactorial nature of the heightened inflammation in PWH, potentially obscuring the effect of diet.